Efficacy and safety of the Ad-GM•CAIX dendritic cell-based vaccine in treating in vivo metastatic renal cell carcinoma compared to sunitinib monotherapy and simultaneous vaccine-sunitinib combination therapy

被引：0
|
作者：
Rampersaud, Edward N. [1 ]
Said, Jonathan W. [2 ]
Bot, Adrian [3 ]
Birkhaueser, Frederic D. [1 ]
Kroeger, Nils [1 ]
Zeng, Gang [1 ]
Kabbinavar, Fairooz F. [1 ]
Ribas, Antoni [4 ]
Pantuck, Allan J. [1 ]
Belldegrun, Arie S. [1 ]
Riss, Joseph [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
[3] Kite Pharma Inc, Los Angeles, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Surg Oncol, Los Angeles, CA 90095 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2819
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2819
引用
收藏
页数：2
相关论文
共 37 条
  • [31] Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan
    Hideaki Miyake
    Akira Miyazaki
    Ken-ichi Harada
    Masato Fujisawa
    Medical Oncology, 2014, 31
  • [32] Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results
    von Weikersthal, Fischer L.
    Vervenne, W. L.
    Goebell, P. J.
    Eichelberg, C.
    Freier, W.
    De Santis, M.
    Zimmermann, U.
    Bos, M. M. E. M. M.
    Trojan, L.
    Lerchenmueller, C.
    Schenck, M.
    Staehler, M.
    Floercken, A.
    Pahernik, S.
    Los, M.
    van Arkel, C.
    Schirrmacher-Memmel, S.
    Michel, M. S.
    ONKOLOGIE, 2012, 35 : 237 - 237
  • [33] Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years
    Miyake, Hideaki
    Aki, Ryota
    Matsushita, Yuto
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    ANTICANCER RESEARCH, 2018, 38 (06) : 3593 - 3599
  • [34] Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results.
    Michel, Maurice Stephan
    Vervenne, Walter
    Goebell, Peter J.
    Von Weikersthal, Ludwig Fischer
    Freier, Werner
    De Santis, Maria
    Zimmermann, Uwe
    Bos, Monique M. E. M.
    Trojan, Lutz
    Lerchenmuller, Christian A.
    Schenk, Marcus
    Staehler, Michael D.
    Floercken, Anne
    Pahernik, Sascha
    Los, Maartje
    Van Arkel, Cornelis
    Schirrmacher-Memmel, Silke
    Eichelberg, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
    Grande, E.
    Alonso-Gordoa, T.
    Reig, O.
    Esteban, E.
    Castellano, D.
    Garcia-Del-Muro, X.
    Mendez, M. J.
    Garcia-Donas, J.
    Rodriguez, M. Gonzalez
    Arranz-Arija, J. A.
    Lopez-Criado, P.
    Molina-Cerrillo, J.
    Mellado, B.
    Alvarez-Fernandez, C.
    De Velasco, G.
    Cuellar-Rivas, M. A.
    Rodriguez-Alonso, R. M.
    Rodriguez-Moreno, J. F.
    Suarez-Rodriguez, C.
    ESMO OPEN, 2022, 7 (02)
  • [36] Efficacy and safety of tyrosine kinase inhibitors alone or in combination with radiation therapy for metastatic renal cell carcinoma A protocol for evidence-based systematic review and Bayesian network meta-analysis
    Wang, Shihua
    Jin, Weihua
    Jiang, Changqing
    Zhang, Yiwen
    Deng, Kaiwen
    MEDICINE, 2021, 100 (33)
  • [37] INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
    Grande, Enrique
    Alonso Gordoa, Teresa
    Reig Torras, Oscar
    Esteban, Emilio
    Castellano, Daniel
    Garcia del Muro, Xavier
    Mendez Vidal, Maria Jose
    Garcia-Donas, Jesus
    Angel Arranz, Jose
    Suarez Rodriguez, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
1234